TNF and uveitis: Analyses of uveitis flares from multiple randomized controlled trials (RCTs), in which patients received anti–tumor necrosis factor (TNF) therapy for the treatment of AS, have demonstrated a significant reduction in the incidence of acute AU flares in AS patients receiving etanercept 16 or infliximab compared to placebo 17.